Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease
Identifieur interne : 000955 ( PascalFrancis/Curation ); précédent : 000954; suivant : 000956Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease
Auteurs : Yoshikuni Mizuno [Japon] ; Nobuo Yanagisawa [Japon] ; Sadako Kuno [Japon] ; Mitsutoshi Yamamoto [Japon] ; Kazuko Hasegawa [Japon] ; Hideki Origasa [Japon] ; Hisayuki Kowa [Japon]Source :
- Movement disorders [ 0885-3185 ] ; 2003.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Adulte.
English descriptors
- KwdEn :
Abstract
We compared the efficacy and safety of pramipexole (PPX) with placebo in the treatment of advanced Parkinson's disease (PD) as an adjunct to levodopa. A bromocriptine (BR) group was included to enable determination of the noninferiority of PPX relative to BR as the standard treatment.
pA |
|
---|
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002366
Links to Exploration step
Pascal:04-0095349Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease</title>
<author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Yanagisawa, Nobuo" sort="Yanagisawa, Nobuo" uniqKey="Yanagisawa N" first="Nobuo" last="Yanagisawa">Nobuo Yanagisawa</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Kanto Rosai Hospital</s1>
<s2>Kawasaki</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Kuno, Sadako" sort="Kuno, Sadako" uniqKey="Kuno S" first="Sadako" last="Kuno">Sadako Kuno</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Center for Neurological disease, Clinical Research Section, Utano National Hospital</s1>
<s2>Kyoto</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Yamamoto, Mitsutoshi" sort="Yamamoto, Mitsutoshi" uniqKey="Yamamoto M" first="Mitsutoshi" last="Yamamoto">Mitsutoshi Yamamoto</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Neurology, Kagawa Prefectural Central Hospital</s1>
<s2>Takamatsu</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Hasegawa, Kazuko" sort="Hasegawa, Kazuko" uniqKey="Hasegawa K" first="Kazuko" last="Hasegawa">Kazuko Hasegawa</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, Sagamihara National Hospital</s1>
<s2>Sagamihara</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Origasa, Hideki" sort="Origasa, Hideki" uniqKey="Origasa H" first="Hideki" last="Origasa">Hideki Origasa</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Division of Biostatistics, Faculty of Medicine, Toyama Medical and Pharmaceutical University</s1>
<s2>Toyama</s2>
<s3>JPN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Kowa, Hisayuki" sort="Kowa, Hisayuki" uniqKey="Kowa H" first="Hisayuki" last="Kowa">Hisayuki Kowa</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Kitasato University</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0095349</idno>
<date when="2003">2003</date>
<idno type="stanalyst">PASCAL 04-0095349 INIST</idno>
<idno type="RBID">Pascal:04-0095349</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002366</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000955</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease</title>
<author><name sortKey="Mizuno, Yoshikuni" sort="Mizuno, Yoshikuni" uniqKey="Mizuno Y" first="Yoshikuni" last="Mizuno">Yoshikuni Mizuno</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Yanagisawa, Nobuo" sort="Yanagisawa, Nobuo" uniqKey="Yanagisawa N" first="Nobuo" last="Yanagisawa">Nobuo Yanagisawa</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Kanto Rosai Hospital</s1>
<s2>Kawasaki</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Kuno, Sadako" sort="Kuno, Sadako" uniqKey="Kuno S" first="Sadako" last="Kuno">Sadako Kuno</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Center for Neurological disease, Clinical Research Section, Utano National Hospital</s1>
<s2>Kyoto</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Yamamoto, Mitsutoshi" sort="Yamamoto, Mitsutoshi" uniqKey="Yamamoto M" first="Mitsutoshi" last="Yamamoto">Mitsutoshi Yamamoto</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Neurology, Kagawa Prefectural Central Hospital</s1>
<s2>Takamatsu</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Hasegawa, Kazuko" sort="Hasegawa, Kazuko" uniqKey="Hasegawa K" first="Kazuko" last="Hasegawa">Kazuko Hasegawa</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, Sagamihara National Hospital</s1>
<s2>Sagamihara</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Origasa, Hideki" sort="Origasa, Hideki" uniqKey="Origasa H" first="Hideki" last="Origasa">Hideki Origasa</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Division of Biostatistics, Faculty of Medicine, Toyama Medical and Pharmaceutical University</s1>
<s2>Toyama</s2>
<s3>JPN</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
<author><name sortKey="Kowa, Hisayuki" sort="Kowa, Hisayuki" uniqKey="Kowa H" first="Hisayuki" last="Kowa">Hisayuki Kowa</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Kitasato University</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Japon</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2003">2003</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvant treatment</term>
<term>Adult</term>
<term>Advanced stage</term>
<term>Bromocriptine</term>
<term>Chemotherapy</term>
<term>Comparative study</term>
<term>Double blind study</term>
<term>Levodopa</term>
<term>Multicenter study</term>
<term>Parkinson disease</term>
<term>Pramipexole</term>
<term>Prognosis</term>
<term>Randomization</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Stade avancé</term>
<term>Pramipexole</term>
<term>Chimiothérapie</term>
<term>Lévodopa</term>
<term>Bromocriptine</term>
<term>Randomisation</term>
<term>Etude double insu</term>
<term>Etude multicentrique</term>
<term>Traitement adjuvant</term>
<term>Etude comparative</term>
<term>Pronostic</term>
<term>Adulte</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Adulte</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We compared the efficacy and safety of pramipexole (PPX) with placebo in the treatment of advanced Parkinson's disease (PD) as an adjunct to levodopa. A bromocriptine (BR) group was included to enable determination of the noninferiority of PPX relative to BR as the standard treatment.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>18</s2>
</fA05>
<fA06><s2>10</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MIZUNO (Yoshikuni)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>YANAGISAWA (Nobuo)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>KUNO (Sadako)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>YAMAMOTO (Mitsutoshi)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>HASEGAWA (Kazuko)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>ORIGASA (Hideki)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>KOWA (Hisayuki)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, Juntendo University School of Medicine</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Kanto Rosai Hospital</s1>
<s2>Kawasaki</s2>
<s3>JPN</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Center for Neurological disease, Clinical Research Section, Utano National Hospital</s1>
<s2>Kyoto</s2>
<s3>JPN</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Neurology, Kagawa Prefectural Central Hospital</s1>
<s2>Takamatsu</s2>
<s3>JPN</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Neurology, Sagamihara National Hospital</s1>
<s2>Sagamihara</s2>
<s3>JPN</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Division of Biostatistics, Faculty of Medicine, Toyama Medical and Pharmaceutical University</s1>
<s2>Toyama</s2>
<s3>JPN</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Kitasato University</s1>
<s2>Tokyo</s2>
<s3>JPN</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA17 i1="01" i2="1"><s1>The Japan Pramipexole Study Group</s1>
<s3>JPN</s3>
</fA17>
<fA20><s1>1149-1156</s1>
</fA20>
<fA21><s1>2003</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000113383090080</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2004 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>25 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>04-0095349</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>We compared the efficacy and safety of pramipexole (PPX) with placebo in the treatment of advanced Parkinson's disease (PD) as an adjunct to levodopa. A bromocriptine (BR) group was included to enable determination of the noninferiority of PPX relative to BR as the standard treatment.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Stade avancé</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Advanced stage</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Estadio avanzado</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Pramipexole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Pramipexole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Pramipexol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Bromocriptine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Bromocriptine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Bromocriptina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Randomisation</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Randomization</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Aleatorización</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Etude double insu</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Double blind study</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Estudio doble ciego</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Etude multicentrique</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Multicenter study</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Estudio multicéntrico</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Traitement adjuvant</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Adjuvant treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Tratamiento adyuvante</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Etude comparative</s0>
<s5>18</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Comparative study</s0>
<s5>18</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Estudio comparativo</s0>
<s5>18</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>19</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>19</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>19</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Adulte</s0>
<s5>20</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Adult</s0>
<s5>20</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Adulto</s0>
<s5>20</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>45</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Agonist</s0>
<s5>45</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Agonista</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Récepteur dopaminergique D2</s0>
<s5>46</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>D2 Dopamine receptor</s0>
<s5>46</s5>
<s6>«D2» Dopamine receptor</s6>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Receptor dopaminérgico D2</s0>
<s5>46</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
<s5>47</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Dopamine agonist</s0>
<s5>47</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
<s5>47</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>48</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>48</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>48</s5>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Neuroprotecteur</s0>
<s5>49</s5>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Neuroprotective agent</s0>
<s5>49</s5>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Neuroprotector</s0>
<s5>49</s5>
</fC07>
<fC07 i1="12" i2="X" l="FRE"><s0>Ergot dérivé</s0>
<s5>53</s5>
</fC07>
<fC07 i1="12" i2="X" l="ENG"><s0>Ergot derivatives</s0>
<s5>53</s5>
</fC07>
<fC07 i1="12" i2="X" l="SPA"><s0>Ergot derivado</s0>
<s5>53</s5>
</fC07>
<fN21><s1>061</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000955 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000955 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PascalFrancis |étape= Curation |type= RBID |clé= Pascal:04-0095349 |texte= Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease }}
This area was generated with Dilib version V0.6.23. |